We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $610M
1-Year Est. Return 40.86%
This Fund
S&P 500
This Quarter Est. Return
+24.97%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$429M
AUM Growth
+$18.7M
Cap. Flow
-$61M
Cap. Flow %
-14.23%
Top 10 Hldgs %
55.8%
Holding
50
New
11
Increased
13
Reduced
18
Closed
8

Top Buys

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$23.4M
2
DXCM icon
DexCom
DXCM
+$9.91M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.57M
4
BSX icon
Boston Scientific
BSX
+$7.88M
5
SEM
Select Medical
SEM
+$6.94M

Top Sells

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$34.3M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$20M
3
FOLD
Amicus Therapeutics
FOLD
+$12.6M
4
ARGX icon
argenx
ARGX
+$12.3M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$10.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.02%
2 Industrials 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KIDS icon
26
OrthoPediatrics
KIDS
$485M
$5.72M 1.33%
308,707
+235,060
+319% +$4.84M
CRBP icon
27
Corbus Pharmaceuticals
CRBP
$170M
$4.34M 1.01%
343,400
-236,493
-41% -$2.25M
RCKT icon
28
Rocket Pharmaceuticals
RCKT
$348M
$4.13M 0.96%
1,267,965
-312,623
-20% -$985K
PRCT icon
29
Procept Biorobotics
PRCT
$950M
$2.75M 0.64%
+76,991
New +$3.52M
ALGN icon
30
Align Technology
ALGN
$12B
$2.43M 0.57%
+19,442
New +$3.05M
ARGX icon
31
argenx
ARGX
$57.4B
$2.43M 0.57%
3,300
-18,700
-85% -$12.3M
TWST icon
32
Twist Bioscience
TWST
$5.62B
$2.11M 0.49%
+75,000
New +$2.27M
AKRO
33
DELISTED
Akero Therapeutics
AKRO
$1.86M 0.43%
+39,072
New +$1.89M
CTMX icon
34
CytomX Therapeutics
CTMX
$705M
$1.8M 0.42%
564,800
-2,952,313
-84% -$6.65M
SGHT icon
35
Sight Sciences
SGHT
$267M
$1.51M 0.35%
439,941
-431,746
-50% -$1.61M
OKUR
36
OnKure Therapeutics
OKUR
$166M
$737K 0.17%
267,959
+108,267
+68% +$268K
SDGR icon
37
Schrodinger
SDGR
$1.12B
$699K 0.16%
+34,830
New +$700K
RNTX
38
Rein Therapeutics
RNTX
$67.7M
$650K 0.15%
567,898
+139,979
+33% +$178K
TBI
39
Trueblue
TBI
$234M
$487K 0.11%
+79,476
New +$503K
PRTA icon
40
Prothena Corp
PRTA
$458M
$195K 0.05%
20,000
-247,800
-93% -$1.9M
PLRX icon
41
Pliant Therapeutics
PLRX
$67.5M
$30.3K 0.01%
20,487
-816,913
-98% -$1.25M
ACTU
42
Actuate Therapeutics
ACTU
$28.2M
$5.92K ﹤0.01%
+885
New +$6.42K
AXGN icon
43
Axogen
AXGN
$2.1B
– –
-282,809
Closed -$3.07M
ERAS icon
44
Erasca
ERAS
$6.63B
– –
-240,295
Closed -$305K
LIVN icon
45
LivaNova
LIVN
$4.3B
– –
-140,000
Closed -$6.3M
LNTH icon
46
Lantheus
LNTH
$6.82B
– –
-34,576
Closed -$2.83M
MIRM icon
47
Mirum Pharmaceuticals
MIRM
$6.89B
– –
-200,000
Closed -$10.2M
MURA
48
DELISTED
Mural Oncology
MURA
– –
-900,000
Closed -$2.22M
PEPG icon
49
PepGen
PEPG
$133M
– –
-243,980
Closed -$271K
UNH icon
50
UnitedHealth
UNH
$382B
– –
-110,000
Closed -$34.3M
1
2

Similar funds

PL
Pandi LLC Leawood, Kansas $610M AUM 14.97% 1-Year Est. Return
BFC
Blue Fin Capital Warren, Rhode Island $610M AUM 26.46% 1-Year Est. Return
DCM
DGS Capital Management Jersey City, New Jersey $609M AUM 44.78% 1-Year Est. Return
SAM
Strategy Asset Managers Pasadena, California $609M AUM 32.56% 1-Year Est. Return
CBB
Citizens Business Bank Ontario, California $610M AUM 27.86% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
FFWA
FRG Family Wealth Advisors Bellevue, Washington $611M AUM 25.92% 1-Year Est. Return
CIP
Convergence Investment Partners Palm Beach Gardens, Florida $611M AUM 61.48% 1-Year Est. Return

Prosight Management's Q3 2025 Portfolio in Review

As of Q3 2025, Prosight Management held 50 positions worth $429M, up 4.6% from $410M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Prosight Management withdrew a net $61M in Q3 2025, closing 8 positions and reducing 18 holdings. Its most notable exit was UnitedHealth, an estimated $34.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 100% a quarter earlier, followed by Industrials.

Against the trend, Prosight Management opened a new position in Intuitive Surgical worth $21.8M.

  • Prosight Management's largest Q3 2025 buy was Intuitive Surgical: 48,711 shares worth $21.8M.
  • Prosight Management added most to DexCom in Q3 2025, an estimated $9.91M increase.
  • Prosight Management's biggest Q3 2025 reduction was Lakefront Biotherapeutics American Depositary Shares, cutting an estimated $20M.
  • Prosight Management fully exited UnitedHealth in Q3 2025, selling an estimated $34.3M.
  • Prosight Management's ten largest holdings make up 56% of its $429M portfolio in Q3 2025.
  • Prosight Management opened 11 new positions and closed 8 in Q3 2025.
  • Prosight Management's portfolio value rose 4.6% quarter-over-quarter to $429M.

Based on Prosight Management's 13F filing for Q3 2025, filed 14 Nov 2025.